13D Filings
ARS Pharmaceuticals, Inc.
SPRY
Amendment
Ownership

8.79%

Total Shares

8,633,537

Issuer CIK

1671858

CUSIP

82835W108

Event Date

Jul 17, 2025

Accepted

Jul 22, 2025, 07:38 PM

Reporting Persons (6)
Joint Filing

This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.

NameType% of ClassAggregateSole VotingShared Voting
Deerfield Management Company, L.P.
Partnership
8.79%8,633,53708,633,537
James E. Flynn
Individual
8.79%8,633,53708,633,537
Deerfield Mgmt III, L.P.
Partnership
4.40%4,316,76804,316,768
Deerfield Private Design Fund III, L.P.
Partnership
4.40%4,316,76804,316,768
Deerfield Mgmt IV, L.P.
Partnership
4.40%4,316,76904,316,769
Deerfield Private Design Fund IV, L.P.
Partnership
4.40%4,316,76904,316,769
Disclosure Items (3)

Security Title

Common Stock, par value $0.0001 per share

Issuer Name

ARS Pharmaceuticals, Inc.

Percentage of Class

(1) Deerfield Mgmt III Number of shares: 4,316,768 (comprised of shares held by Deerfield Private Design Fund III) Percentage of shares: 4.40% (2) Deerfield Private Design Fund III Number of shares: 4,316,768 Percentage of shares: 4.40% (3) Deerfield Mgmt IV Number of shares: 4,316,769 (comprised of shares held by Deerfield Private Design Fund IV)? Percentage of shares: 4.40% (4) Deerfield Private Design Fund IV Number of shares: 4,316,769 Percentage of shares: 4.40% (5) Deerfield Management Number of shares: 8,633,537 (comprised of shares held by Deerfield Private Design Fund III and Deerfield PrivateDesign Fund IV) Percentage of shares: 8.79% (6) Flynn Number of shares: 8,633,537 (comprised of shares held by Deerfield Private Design Fund III and Deerfield PrivateDesign Fund IV) Percentage of shares: 8.79%

Number of Shares

(1) Deerfield Mgmt III Sole power to vote or direct the vote: 0 Shared power to vote or direct the vote: 4,316,768 Sole power to dispose or to direct the disposition: 0 Shared power to dispose or direct the disposition: 4,316,768 (2) Deerfield Private Design Fund III Sole power to vote or direct the vote: 0 Shared power to vote or direct the vote: 4,316,768 Sole power to dispose or to direct the disposition: 0 Shared power to dispose or direct the disposition: 4,316,768 (3) Deerfield Mgmt IV Sole power to vote or direct the vote: 0 Shared power to vote or direct the vote: 4,316,769 Sole power to dispose or to direct the disposition: 0 Shared power to dispose or direct the disposition: 4,316,769 (4) Deerfield Private Design Fund IV Sole power to vote or direct the vote: 0 Shared power to vote or direct the vote: 4,316,769 Sole power to dispose or to direct the disposition: 0 Shared power to dispose or direct the disposition: 4,316,769 (3) Deerfield Management Sole power to vote or direct the vote: 0 Shared power to vote or direct the vote: 8,633,537 Sole power to dispose or to direct the disposition: 0 Shared power to dispose or direct the disposition: 8,633,537 (6) Flynn Sole power to vote or direct the vote: 0 Shared power to vote or direct the vote: 8,633,537 Sole power to dispose or to direct the disposition: 0 Shared power to dispose or direct the disposition: 8,633,537 Flynn is the managing member of the general partner of each of Deerfield Mgmt IV, Deerfield Mgmt III and Deerfield Management. Deerfield Mgmt III is the general partner of Deerfield Private Design Fund III and Deerfield Mgmt IV is the general partner of Deerfield Private Design Fund IV. Deerfield Management is the investment manager of the Deerfield Funds. *Percentage beneficial ownership reported herein reflects 98,213,561 shares of Common Stock outstanding as of May 12, 2025, as reported by the Company in its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025.

Transactions

Transactions in the Common Stock effected by the Reporting Persons since the filing of Amendment No. 3 to the Schedule 13D are set forth on Schedule A to this Amendment. All transactions reflected in Schedule A to this Amendment were effected in open market transactions on the Nasdaq Global Market in the ordinary course of the applicable Reporting Person's business.

Exhibit 99.3 - Schedule A: Transactions in Securities